MX2020004608A - Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia. - Google Patents

Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia.

Info

Publication number
MX2020004608A
MX2020004608A MX2020004608A MX2020004608A MX2020004608A MX 2020004608 A MX2020004608 A MX 2020004608A MX 2020004608 A MX2020004608 A MX 2020004608A MX 2020004608 A MX2020004608 A MX 2020004608A MX 2020004608 A MX2020004608 A MX 2020004608A
Authority
MX
Mexico
Prior art keywords
compositions
methods
crispr
cells
tgfbr2
Prior art date
Application number
MX2020004608A
Other languages
English (en)
Inventor
Fred Harbinski
Stephen Michael Burleigh
Christopher Heath Nye
Blythe D Sather
Queenie Vong
Gordon Grant Welstead
Melissa Chin
Chris Wilson
Original Assignee
Editas Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc filed Critical Editas Medicine Inc
Publication of MX2020004608A publication Critical patent/MX2020004608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Se proporcionan sistemas, composiciones y metodos de edicion de genoma relacionado con CRISPR/CAS para la direccion del locus TGEBR2, asi como celulas editadas utilizando estos sistemas, composiciones y metodos.
MX2020004608A 2017-11-01 2018-11-01 Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia. MX2020004608A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580320P 2017-11-01 2017-11-01
PCT/US2018/058635 WO2019089884A2 (en) 2017-11-01 2018-11-01 Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy

Publications (1)

Publication Number Publication Date
MX2020004608A true MX2020004608A (es) 2020-10-05

Family

ID=64453598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004608A MX2020004608A (es) 2017-11-01 2018-11-01 Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia.

Country Status (13)

Country Link
US (1) US20230061455A1 (es)
EP (1) EP3704251A2 (es)
JP (2) JP2021502113A (es)
KR (1) KR20200075000A (es)
CN (1) CN111527209A (es)
AU (1) AU2018358250A1 (es)
BR (1) BR112020008478A2 (es)
CA (1) CA3081456A1 (es)
IL (1) IL274299A (es)
MA (1) MA50858A (es)
MX (1) MX2020004608A (es)
SG (1) SG11202003862PA (es)
WO (1) WO2019089884A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
BR112021021075A2 (pt) * 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
WO2020243361A1 (en) 2019-05-29 2020-12-03 Monsanto Technology Llc Methods and compositions for generating dominant short stature alleles using genome editing
MX2021014528A (es) * 2019-05-29 2022-01-06 Monsanto Technology Llc Metodos y composiciones para generar alelos dominantes usando edicion del genoma.
JP2022535429A (ja) * 2019-06-04 2022-08-08 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
EP3999527A4 (en) * 2019-07-18 2024-04-17 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
US20230009232A1 (en) * 2019-11-20 2023-01-12 Cartherics Pty. Ltd. Method for providing immune cells with enhanced function
WO2021127261A1 (en) * 2019-12-17 2021-06-24 The General Hospital Corporation Engineered immune cells with reduced toxicity and uses thereof
KR20220119063A (ko) * 2019-12-18 2022-08-26 에디타스 메디신, 인코포레이티드 치료용 조작 세포
EP4119166A4 (en) 2020-03-12 2024-06-05 Institute for Basic Science COMPOSITION FOR INDUCING APOPTOSIS OF CELLS HAVING GENOMIC SEQUENCE VARIATION AND METHOD FOR INDUCING APOPTOSIS OF CELLS USING THE COMPOSITION
EP4176048A1 (en) 2020-09-23 2023-05-10 CRISPR Therapeutics AG Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023147428A2 (en) * 2022-01-26 2023-08-03 Orthobio Therapeutics, Inc. Gene editing to improve joint function
WO2023180967A1 (en) * 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2024058589A1 (ko) * 2022-09-16 2024-03-21 한국과학기술연구원 유전자 가위 넉-인을 이용하여 제조한 키메릭 항원 수용체 세포 및 이의 용도
CN116515766A (zh) * 2023-06-30 2023-08-01 上海贝斯昂科生物科技有限公司 一种自然杀伤细胞、其制备方法及用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
AU742650B2 (en) 1997-10-02 2002-01-10 Altor Bioscience Corporation Soluble single-chain T-cell receptor proteins
EP1066380B1 (en) 1998-05-19 2001-11-14 Avidex Ltd Soluble t cell receptor
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
AU2001265346A1 (en) 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
DE602005022595D1 (de) 2004-06-29 2010-09-09 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
AU2005291039A1 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
JP5840837B2 (ja) 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG10201602253SA (en) 2011-03-23 2016-05-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN107011426B (zh) 2011-11-11 2021-05-14 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
SI2884999T1 (sl) 2012-08-20 2021-05-31 Fred Hutchinson Cancer Research Center Metoda in sestavki za celično imunoterapijo
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250T5 (de) 2012-12-20 2015-10-08 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
EP3011035B1 (en) * 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
EP3363903B1 (en) 2013-11-07 2024-01-03 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
CA2948728A1 (en) 2014-03-10 2015-09-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
EP3215617B1 (en) 2014-11-07 2024-05-08 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
IL295616A (en) * 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
EP3347026A4 (en) * 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY

Also Published As

Publication number Publication date
MA50858A (fr) 2020-09-09
JP2021502113A (ja) 2021-01-28
RU2020117752A (ru) 2021-12-01
US20230061455A1 (en) 2023-03-02
KR20200075000A (ko) 2020-06-25
CA3081456A1 (en) 2019-05-09
BR112020008478A2 (pt) 2020-10-20
WO2019089884A3 (en) 2019-06-13
WO2019089884A2 (en) 2019-05-09
SG11202003862PA (en) 2020-05-28
IL274299A (en) 2020-06-30
CN111527209A (zh) 2020-08-11
AU2018358250A1 (en) 2020-05-14
JP2023179469A (ja) 2023-12-19
EP3704251A2 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
MX2020004608A (es) Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia.
SG10201906070XA (en) Compositions and methods for high efficiency in vivo genome editing
MX2020004830A (es) Medios y metodo para preparar vectores virales y usos de los mismos.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12018501159A1 (en) Composition and methods for immunooncology
MX2020004541A (es) Edicion de genes de celulas primarias.
EP4275747A3 (en) Therapeutic applications of cpf1-based genome editing
WO2014165825A3 (en) Therapeutic uses of genome editing with crispr/cas systems
EP4339287A3 (en) Modified cells and methods of therapy
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
PH12021550849A1 (en) Compositions and methods for immunotherapy
EP4389889A3 (en) Compositions and methods for editing rna
EP4317447A3 (en) Donor repair templates multiplex genome editing
PH12016502162A1 (en) Multiplex gene editing in swine
BR112017012765A2 (pt) ?métodos para editar uma sequência de nucleotídeos, célula e linhagem de e. coli e método para produzir uma célula de e. coli?
MX2017010746A (es) Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas.
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX2020004043A (es) Composiciones y métodos para la edición génica de hemofilia a.
PH12019502171A1 (en) Composition and methods for immunooncology
MX2019004156A (es) Variantes de endonucleasa homing de receptor de linfocitos t alfa (tcralpha).
MX2020003605A (es) Manipulación del metabolismo de triptamina.
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2020011470A (es) Metodos de terapia genica.
MX2021014528A (es) Metodos y composiciones para generar alelos dominantes usando edicion del genoma.